Diastolic Dysfunction in Sickle Cell Disease During Vaso-occlusive Crisis

This study is currently recruiting participants. (see Contacts and Locations)
Verified September 2012 by King Abdullah International Medical Research Center
Sponsor:
Collaborator:
King Abdulaziz Medical City
Information provided by (Responsible Party):
Abdulsalam Alaithan, King Abdulaziz Medical City
ClinicalTrials.gov Identifier:
NCT01683968
First received: September 8, 2012
Last updated: September 12, 2012
Last verified: September 2012
  Purpose

This study is designed to investigate the presence and absence of abnormal heart muscle contractions during sickle cell crises.

You will be asked to do echocardiography during and after your admission to the hospital. We will compare tow pictures and study the differences.


Condition
Sickle Cell

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Diastolic Dysfunction in Sickle Cell Disease During Vaso-occlusive Crisis

Resource links provided by NLM:


Further study details as provided by King Abdullah International Medical Research Center:

Estimated Enrollment: 216
Study Start Date: September 2012
Estimated Study Completion Date: October 2015
Estimated Primary Completion Date: October 2015 (Final data collection date for primary outcome measure)
Groups/Cohorts
Sickle cell
Patient who are admitted with sickle cell crises

  Show Detailed Description

  Eligibility

Ages Eligible for Study:   14 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Adult patient admitted to the hospital with vaso-occlusive crisis

Criteria

Inclusion criteria:

  1. Patients older than 18 years
  2. Diagnosis of acute vaso-occlusive crisis due to sickle cell disease.
  3. Informed consent

Exclusion criteria:

  1. Congenital heart disease
  2. Long standing hypertension
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01683968

Contacts
Contact: Dr Abdulsalam M Alaithan, MD 96635910000 ext 33445 aithana@ngha.med.sa

Locations
Saudi Arabia
King Abdulaziz Hospital Recruiting
Al-Ahsa, EP, Saudi Arabia, 31982
Contact: Abdulsalam MA Alaithan, MD    96635910000 ext 33445    aithana@ngha.med.sa   
Sponsors and Collaborators
King Abdullah International Medical Research Center
King Abdulaziz Medical City
  More Information

No publications provided

Responsible Party: Abdulsalam Alaithan, CONSULTANT INTENSIVEST AND PULMONOLOGIST, King Abdulaziz Medical City
ClinicalTrials.gov Identifier: NCT01683968     History of Changes
Other Study ID Numbers: RE11/027
Study First Received: September 8, 2012
Last Updated: September 12, 2012
Health Authority: Saudi Arabia: Ethics Committee

Additional relevant MeSH terms:
Anemia, Sickle Cell
Anemia, Hemolytic, Congenital
Anemia, Hemolytic
Anemia
Hematologic Diseases
Hemoglobinopathies
Genetic Diseases, Inborn

ClinicalTrials.gov processed this record on October 01, 2014